Stock Evaluator: Lycia Therapeutics, Inc. (LYCA)

Lycia Therapeutics, Inc. LYCA

$28.82 -2.38 -7.63%
November 16, 2026 3:46:16 PM EST November 10, 2021 Volume: 192,700
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy. The company also develops LCA-0062, a follow-on program designed to degrade IgE for the treatment of allergic diseases. Additionally, it develops LCA-0321, a candidate designed to selectively degrade TSHR autoantibodies (thyrotropin receptor antibodies, or TRAbs), the pathogenic drivers of Graves' disease. Lycia Therapeutics, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Commentary & Analysis


Financial Summary

Share Statistics LYCA Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,799.6 $211.8 53%
Shares Out (Mil) 14.5 55.4 26%
Institutional Ownership 78.1% 93.0% 47%
Float (Mil) 33.8 41.5 38%
Beta na 0.99 na
Avg Daily Volume (000s) 277 553 49%
Price Change
(52-week)
na 42.8% na
Growth LYCA Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) na (10.3%) na
EPS (5yr) na 15.8% na
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) na (15.7%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials LYCA Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $4 $41 5%
Net Income (TTM) (Mil) ($30) ($44) 20%
EPS (TTM) ($2.091) ($1.500) 14%
Operating Cash Flow (TTM) (Mil) ($34) ($35) 12%
Net Cash Flow (TTM) (Mil) $36 $-0 68%
Long-Term Debt (Q1) (Mil) $2 $4 19%
Enterprise Value (Q1) (Mil) $1,732 $147 48%
Valuation LYCA Industry
Median
Percentile
(All Stocks)
P/B na 2.01 na
P/E na 17.9 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.0 na
Ratios LYCA Industry
Median
Percentile
(All Stocks)
Gross Margin 291.5% 67.9% 100%
Net Margin (677.2%) (50.6%) 1%
ROA (38.3%) (47.4%) 14%
ROE 45.5% (53.1%) 92%
Liabilities to Assets 7.6% 29.7% 4%
F-Score 0 3 na

Lycia Therapeutics, Inc. did not pass any screens on 11/13/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors